In this article, we analyse the European Union’s strategy for the Life Sciences sector and the roadmap to 2030, exploring investments, innovation policies, regulatory simplification and digital interoperability, with particular attention to the strategic role of compliant and professional multilingual communication for companies operating in the European market.
The European Union has outlined an ambitious roadmap to achieve global leadership in the Life Sciences sector by 2030. With annual investments exceeding €15 billion, the EU is building an ecosystem that integrates biotechnology, pharmaceuticals, digital health, and sustainable agriculture.
The strategy is built around three pillars: technological and health sovereignty, innovation and competitiveness through simplified regulatory processes, and digital interoperability. The new Biotech Act introduces €10 billion in investments, while EU4Health (over €5 billion) and Horizon Europe (€95.5 billion) provide funding for research and innovation. For companies, this transformation poses a crucial challenge: preparing for compliant and professional multilingual communication, which is essential to access the integrated European market.
Choose Europe for Life Sciences and the Biotech Act
Launched on 2 July 2025, the Choose Europe for Life Sciences [1] strategy represents the overarching political and industrial framework through which the European Union aims to strengthen its global leadership in the sector. The initiative seeks to consolidate European health autonomy, accelerate innovation across the entire Life Sciences value chain, and promote the digitalisation of research, development, and production systems. At its core is the creation of an ecosystem that is attractive to investments, talent, and businesses, capable of competing with the United States and Asia not only in basic research, but also in the industrial valorisation of innovation.
Within this context sits the Biotech Act [2], proposed by the European Commission on 16 December 2025, which constitutes the main legislative instrument for implementing the strategy. The measure stems from a critical observation: despite excelling in scientific research, Europe struggles to transform biotechnological innovation into scalable commercial products. High-tech start-ups and SMEs often relocate outside the EU during the scale-up and commercialisation phases, attracted by more favourable financial, regulatory, and industrial ecosystems.
The Biotech Act aims to reverse this trend through an integrated regulatory package that addresses the sector’s main bottlenecks: access to early-stage capital, protection of intellectual property, simplification of authorisation pathways, and technical-scientific support. The objective is to create the conditions for biotechnological innovations to be conceived, developed and scaled entirely within the European market, in line with the strategic vision outlined by Choose Europe for Life Sciences.
The Biotech Act is currently under discussion in the European Parliament and the Council, with final adoption not expected before the end of 2026. Once approved, it will represent one of the most significant interventions of recent decades to structurally strengthen the European biotechnology sector.
EU Funding: EU4Health and Horizon Europe
The European Union has strengthened its commitment to the healthcare sector through two complementary funding programmes that represent a strategic response to public health challenges and scientific innovation.
EU4Health [3] marks a turning point in European health policy, with a budget of over €5 billion for the 2021–2027 period – the largest ever allocated by the EU to health. Managed by the HaDEA Executive Agency, the programme funds initiatives ranging from disease prevention to pandemic preparedness, with the aim of making European healthcare systems more resilient and accessible.
Horizon Europe, the framework programme for research and innovation with a budget of €95.5 billion, allocates significant resources to the Life Sciences sector through pan-European consortia. The programme supports European health missions, promoting advances in precision medicine, biotechnology and digital health, and fostering the transformation of scientific discoveries into tangible solutions for patients and healthcare systems.
The European strategy amplifies the critical role of multilingual communication
Within this political, legislative, and industrial framework, multilingual communication becomes essential, and linguistic precision a critical component of regulatory compliance and patient safety. Clinical protocols, technical dossiers, package leaflets, and labelling must comply with stringent regulatory requirements.
- Mandatory regulatory compliance: Directive 2001/83/EC requires medicinal information and labelling to be provided in the official languages of the Member States; Regulation MDR 2017/745 imposes similar requirements for medical devices [4]; the EMA requires linguistic review [5] in all 24 official EU languages.
- Patient safety: translation errors related to dosages, contraindications or instructions for use can cause serious adverse events and compromise the effectiveness of therapies.
- Economic impact: non-compliant translations lead to delays in market entry, reprints, rework, and product recalls, with potentially multimillion-euro economic consequences.
- Multilingual complexity: with 24 official languages and country-specific requirements, managing regulatory and clinical documentation becomes extremely complex and requires a high level of coordination.
Multilingual communication: a strategic factor
The European Life Sciences roadmap further amplifies the critical importance of multilingual communication. Digital interoperability with infrastructures such as the EHDS [6] (European Health Data Space), CTIS (Clinical Trial Information System) and e-labelling systems requires structured, consistent, and real-time multilingual content, while regulatory simplification accelerates the timelines for producing compliant documentation. European regulations also emphasise the importance of clear and comprehensible information to ensure transparency and build patient trust.
Addressing these challenges requires going beyond linguistic accuracy alone: it is necessary to build an integrated ecosystem combining specialised medical-scientific expertise, advanced technologies (CAT tools, translation memories, terminology databases) and structured processes with traceable workflows and measurable quality KPIs. Integration with corporate systems such as CTMS (Clinical Trial Management Systems) further ensures consistency and efficiency throughout the entire development lifecycle. A well-defined linguistic strategy thus becomes a strategic asset for anticipating regulatory requirements, accelerating time-to-market, and successfully penetrating the European market.
Opportunities for SMEs and start-ups
Small and medium-sized enterprises account for 99% of companies in the European Union and represent a fundamental driver of innovation in the Life Sciences sector. EMA data show that between 2005 and 2015, around half of the authorisations granted to SMEs concerned medicines with entirely new active substances, while 42% focused on rare diseases. The European Union recognises this strategic role through dedicated support tools, such as the EMA’s SME Office, which assists over 1,700 registered companies, and the new European biotechnology support network envisaged by the Biotech Act, designed to guide SMEs and start-ups through regulatory pathways and access to funding.
Alongside these opportunities, however, significant challenges also emerge. The complexity of European regulations and the need to manage documentation in multiple languages can slow development and generate unforeseen costs. A well-planned linguistic strategy not only reduces delays and expenses, but also strengthens a company’s credibility in the eyes of regulatory authorities and investors, facilitating expansion into the integrated European market. To support this growth, the EU provides targeted funding programmes: EU4Health, Horizon Europe with its innovation accelerator, and BioTechEU, which allocates €10 billion for the 2026–2027 period specifically for biotechnology SMEs and start-ups.
Towards 2030: the potential of Europe’s transformation
The European strategy represents one of the most ambitious investments ever undertaken: over €15 billion per year through EU4Health, Horizon Europe and BioTechEU, with €300 million dedicated to innovative public procurement. The Biotech Act will introduce regulatory sandboxes (controlled testing environments that allow innovative technologies to be trialled under temporary regulatory exemptions, under the supervision of authorities) and extensions of supplementary protection certificates. The 2023 pharmaceutical reform modernises rules that are more than twenty years old. Integrated digital infrastructures (CTIS, EHDS, e-labelling) create an interoperable ecosystem.
The objective is to position Europe as a global leader by 2030, attracting international talent and investment. For companies, the opportunities are significant: dedicated funding, simplified processes, SME support, and access to a market of over 450 million consumers.
This transformation, however, requires a harmonised and compliant ecosystem. Professional multilingual communication becomes a decisive strategic factor. The ability to produce accurate and culturally appropriate documentation in all European languages is no longer merely an operational issue, but the element that makes the difference between success and exclusion from the market. Companies that invest today in robust linguistic processes integrated with European digital systems will be best positioned to fully harness the potential of the largest transformation of the European Life Sciences sector in recent decades.
Aglatech14 ContenTalkers
[1] https://research-and-innovation.ec.europa.eu/strategy/strategy-research-and-innovation/jobs-and-economy/strategy-european-life-sciences_en
[2] https://health.ec.europa.eu/publications/proposal-regulation-establish-measures-strengthen-unions-biotechnology-and-biomanufacturing-sectors_en
[3] https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthier-european-union_en
[4] https://health.ec.europa.eu/document/download/aa9760e3-c864-4173-8b16-d790dac66d74_en?filename=md_sector_lang-req-table-mdr.pdf
[5] https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/product-information-requirements/linguistic-review-human
[6] https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space-regulation-ehds_en
